{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-25-000067","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.563440+00:00","generated_at":"2026-05-26T02:15:15.037705+00:00","sec_items":["1.01","1.02","2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Denali reports FY2024 net loss $422.8M; BLA for MPS II drug planned early 2025","bullets":["Net loss $114.8M Q4 and $422.8M FY2024, vs $119.5M and $145.2M in prior year.","No collaboration revenue in 2024; FY2023 had $330.5M from Biogen, Sanofi, Takeda.","New ATM equity facility up to $400M; prior ATM terminated; Goldman & Leerink agents.","DNL343 (ALS) missed primary endpoint in HEALEY trial; further analyses expected H2 2025.","2025 cash opex guided +10-15% vs 2024; cash balance $1.19 billion as of Dec 31."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-25-000067","json":"https://secwatch.observer/filing/0001714899-25-000067.json","markdown":"https://secwatch.observer/filing/0001714899-25-000067.md","text":"https://secwatch.observer/filing/0001714899-25-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000067/0001714899-25-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000067/dnli-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:15:15.037705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}